2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 882

Polymyalgia Rheumatica Activity Score without C-Reactive Protein
Abstract Number: 883

Folate Receptor Beta and Endothelin Receptor Beta Macrophage Subtypes Are Differentially Expressed in the Vascular Compartments of the Intima and Media/Adventitia in Giant Cell Arteritis: A Pilot Study
Abstract Number: 884

Health-Related Quality of Life in Giant Cell Arteritis
Abstract Number: 885

Giant Cell Arteritis and Malignancy – More Than Just a Coincidence?
Abstract Number: 886

Vascular Inflammation Assessed By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) Is Modified By Treatment in Patients with Large Vessel Vasculitis
Abstract Number: 887

Fatigue and Physical Functioning in Patients with Giant Cell Arteritis
Abstract Number: 888

Prevalence of Takayasu Arteritis in Young Women Presenting with Acute Ischemic Heart Disease
Abstract Number: 889

The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis
Abstract Number: 890

Health-Related Domains of Importance to Patients with Takayasu’s Arteritis
Abstract Number: 891

Clinal Characterisitics and Diagnosis of Patients with Negative Temporal Artery Biopsy and without a Final Diagnosis of Giant Cell Arteritis
Abstract Number: 892

FDG-PET CT Evaluation By Visual Grading Is Not Sufficiently Discriminative to Assess Disease Activity in Takayasu’s Arteritis Patients with ‘Persistent’ Disease
Abstract Number: 893

Preliminary Results of a Multi Modal Imaging Study Suggests a Better Accuracy for the Diagnosis of Giant Cell Arteritis
Abstract Number: 894

Laboratory Tests in Giant Cell Arteritis – Do They Make the Cut?
Abstract Number: 895

Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Abstract Number: 896

Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].